Expert Review of Precision Medicine and Drug Development

Expert Review of Precision Medicine and Drug Development is published by Taylor & Francis and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Pharmacogenetics and Drug Metabolism, together about 29% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

This journal has ceased (2025) *Please note that Expert Review of Precision Medicine and Drug Development converted to a full Open Access journal from Volume 8 (2023). Previous volumes will continue to provide access through a Pay to Read model. Expert Review of Precision Medicine and Drug Development [e-ISSN 2380-8993] is an international open access journal publishing rigorously peer-reviewed review articles and original papers on the development and clinical application of medicine to be used in a personalised therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, Expert Review of Precision Medicine and Drug Development supports the necessity to identify patients responsive to treatments and treat patient populations using a tailored approach. Articles focus on the following key areas: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this; Clinical trials within personalised therapy and drug development; Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment; Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies; Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues. Please note that the journal does not publish case reports, case series or animal studies Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Precision Medicine and Drug Development, part of the Expert Collection brand. For any pre-submission enquiries, please contact the Commissioning Editor. Sorry

From the journal's Aims & Scope

Research area (LetPub): PHARMACOLOGY & PHARMACY

Editor-in-chief Liang ChengPublisher website

Editorial board by country: none in mainland China; most named United States 7, Italy 3, Hong Kong, China 2, United Kingdom 2, Spain 2 (25 members with a country) Editorial board ↗Publisher website · 2026-11-01

CAS Journal Ranking

CiteScore quartiles (Scopus, June 2026 release)

Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub

Database indexing

ESCIScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

CiteScore 2026-06

2.3LetPub · 2026-11-01

SJR 2026-06

0.25LetPub · 2026-11-01

SNIP 2026-06

0.33LetPub · 2026-11-01

h-index

22OpenAlex · 2026-11-01

i10-index

70OpenAlex · 2026-11-01

2-year mean citedness

3.9OpenAlex · 2026-11-01

Self-citation rate

0%LetPub · 2026-11-01

Share of gold OA articles

20%LetPub · 2026-11-01

Volume

Articles per year

4LetPub · 2026-11-01

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Taylor & Francis

ISSN

2380-8993

Latest issue on the website

Volume 10, Issue 1 (2025)

Official links

• Journal homepage ↗LetPub